INTI Inhibitor Therapeutics, Inc. - 8-K

Item
7.01.

Regulation
FD Disclosure.

On
February 24, 2026, Inhibitor Therapeutics, Inc. (the “ Company ”) filed a Current Report on Form 8-K (the “February
24 th Form 8-K”) with the Securities and Exchange Commission (the “Commission”) reporting that it had entered
into a Securities Purchase Agreement (the “ SPA ”) with an institutional investor (the “ Investor ”),
for certain financing (the “Financing”), pursuant to which the Company agreed to sell to the Investor 12,000,000 shares of
its common stock, par value $0.0001 per share (the “Common Stock”) and to issue to the Investor a Common Stock Purchase Warrant
to purchase up to 7,000,000 shares of Common Stock (the “Warrant”), in consideration for the Investor’s investment
of $3,000,000 therefor ($0.25 per share of Common Stock and accompanying Warrant). Descriptions of the SPA and the Warrant are included
in the February 24 th Form 8-K, and each are filed as exhibits thereto.

On
March 30, 2026, the Company initiated litigation against the Investor, as a result of the Investor’s failure to complete the Financing
and perform its obligations under the SPA including, without limitation, funding the $3,000,000 investment in the Company provided therein,
after several attempts by the Company to secure the funds from the Investor without litigation. More detailed information relating to
this litigation will be provided by the Company, when it is available, in a subsequent Current Report on Form 8-K to be filed with the
Commission.

Item
9.01

Financial
Statements and Exhibits.

(d)
The following exhibit is filed with this report.

Exhibit
No.

Description
of Exhibit

104

Cover
Page Interactive Data File (embedded within the Inline XBRL document).